Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 12/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433217 | 0.80 | APP (0.53) | APPGLAGAASNCA | |
| SCHEMBL2428728 | 0.80 | APP (0.53) | APPGLAGAASNCA | |
| SCHEMBL2429116 | 0.77 | CYP3A4 (0.44) | APPGLAGAASNCA | |
| SCHEMBL2430009 | 0.71 | CYP3A4 (0.44) | APPGAA | |
| SCHEMBL5429982 | 0.68 | APP (0.83) | APPGLAGAASNCA | |
| SCHEMBL13806242 | 0.66 | APP (0.75) | APPGLAGAASNCA | |
| SCHEMBL21566066 | 0.65 | APP (0.69) | APPGLAGAASNCA | |
| SCHEMBL2427824 | 0.65 | APP (0.59) | APP | |
| SCHEMBL26017584 | 0.65 | APP (0.76) | APPGLAGAASNCA | |
| SCHEMBL5421230 | 0.65 | SMN1; SMN2 (0.78) | APPGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1956013-B1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | FUJIFILM RI PHARMA CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8022075-B2 | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition | FUJIFILM RI PHARMA CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20090162283-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | FUJIFILM RI PHARMA CO., LTD. (JP) | 2009-06-25 | — | — | US | disclosed |
| EP-1956013-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | Fujifilm RI Pharma Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162283-A1 | DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION | APP, TTR, BACE1 | APP 1/4885GLA 301/4885GAA 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.